BioSpace News Archive

Assertio Holdings, Inc., a commercial-stage pharmaceutical company, announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported that an independent study conducted in Madrid, Spain has confirmed the high performance characteristics of the Company’s MosaiQ COVID-19 Antibody Microarray.

Ensuring supplies and medications are where they are needed, when they are needed has never been simple, even before COVID-19.

Orchard Therapeutics, a global gene therapy leader, announced that the company has received both orphan drug designation and rare pediatric disease designation from the U.S Food and Drug Administration for OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I.

Anika Therapeutics, Inc., a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, announced U.S. Food and Drug Administration clearance and the planned launch of multiple new product innovations that address the needs of orthopedic and sports medicine surgeons and their patients seeking to stay active by overcoming soft tissue damage.

Molecular Partners AG announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency and the Japanese Regulatory Agency for abicipar pegol, a novel DARPin therapeutic for patients with neovascular age-related macular degeneration.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in recurrent glioblastoma.

Freeline announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering in the United States of its American Depositary Shares, each representing one ordinary share.

Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year

A report by TMR Research bearing the title, “Human microbiome Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025” delves into the current and future scenario of the market for human microbiome.